Dergiler / Klinik Psikofarmakoloji Bülteni / 2016 / Cilt: 26 - Sayı: 4

Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide

Sayfa
329–331
DOI
—